Arcellx reports 100% ORR, 76% CR rate in Phase 1 CART-ddBCMA trial; median follow-up 22 mo

Arcellx, Inc.

Overall response rate 100% per IMWG criteria; 29/38 patients (76%) achieved CR or sCR.
Median duration of response, PFS, and OS not reached at 22 months median follow-up.
6-, 12-, 18-month PFS rates by KM: 92%, 74%, 67%. Durable in high-risk subgroups.
All 38 patients triple-refractory; 68% penta-refractory; 89% refractory to last line.
CART-ddBCMA well tolerated; manageable CRS/ICANS, no delayed neurotoxicity or parkinsonism.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.